This review comprehensively overviews the biological characteristics and function of TIM-3 and PD-1 in cancer immunology, elucidates the underlying mechanisms, examines the combined effects of co-inhibiting PD-1/PD-L1 and TIM-3, and evaluates ongoing clinical studies involving this combination treatment. The gene discussed is HAVCR2; the disease is cancer.